Drugs / TELIMOMAB ARITOX
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04168333 Comparator | Jan 2018 → Oct 2019 | chronic hepatitis B virus infection | Tasly Tianjin Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04189276 Comparator | Dec 2019 → Jun 2021 | hepatitis B virus infection | Tasly Tianjin Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TELIMOMAB ARITOX | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108790 ↗ |
| Known as | T101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04189276 ↗ |
| Modality | Vaccine | “is used as therapeutic vaccine for chronic hepatitis B patients” NCT04168333 ↗ |
| Route | Subcutaneous | “will be subcutaneously injected with different dose level of T101” NCT04168333 ↗ |
| Target | CD5 | “T-cell surface glycoprotein CD5 binding agent” CHEMBL2108790 ↗ |